Business Insights

QbD and PAT in Biopharmaceutical Development

July 12, 2022

QbD and PAT
As the pharmaceutical industry tries to embrace the
methodologies of quality by design (QbD) provided
by the FDA ’s process validation (PV) guidance (1) and
International Conference on Harmonization.

Spotlight

DeltaHealth China

DeltaHealth is an innovative healthcare provider primarily invested by Eight Roads and its affiliate Eight Roads Ventures China. As of now, it is also the first and the only medical institution with a consultation and advisory relationship with Columbia HeartSource in China. DeltaHealth is committed to establishing an integrated network of hospitals and clinics in China that specializes in cardiovascular care and always puts patients first. We aim to bring to our patients a set of innovative and personalized medical services. To achieve this, we are building on some of the great medical management practices in the West while combining the world's excellent physicians and state-of-the-art medical technology under one roof. In addition to providing diverse and high-quality healthcare services, we also strive to improve the diagnosis and treatment of cardiovascular diseases, and deliver better experience for patients. We see this as our contribution to the development of the medical syste

OTHER WHITEPAPERS
news image

How to improve manufacturing process efficiency to increase speed-to-market

whitePaper | November 18, 2022

Research by McKinsey on the operational practices of more than 25 global pharmaceutical manufacturers found that the top companies are more than twice as productive as their counterparts.

Read More
news image

Paving the way for pharma R&D to use FAIR data

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

Read More
news image

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

Read More
news image

Medical Afairs Transformation in Specialty Pharma

whitePaper | March 6, 2022

Pharmaceutical companies with a medical mindset and an empowered Medical Afairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates.

Read More
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More
news image

Latest Evidence and Effects of Vitamin D3 (cholecalciferol)-Drug Interactions

whitePaper | October 15, 2022

Because vitamin D receptors are present in most cells in the body, its active form has potent effects on the growth and differentiation of many types of cells, meaning that vitamin D

Read More

Spotlight

DeltaHealth China

DeltaHealth is an innovative healthcare provider primarily invested by Eight Roads and its affiliate Eight Roads Ventures China. As of now, it is also the first and the only medical institution with a consultation and advisory relationship with Columbia HeartSource in China. DeltaHealth is committed to establishing an integrated network of hospitals and clinics in China that specializes in cardiovascular care and always puts patients first. We aim to bring to our patients a set of innovative and personalized medical services. To achieve this, we are building on some of the great medical management practices in the West while combining the world's excellent physicians and state-of-the-art medical technology under one roof. In addition to providing diverse and high-quality healthcare services, we also strive to improve the diagnosis and treatment of cardiovascular diseases, and deliver better experience for patients. We see this as our contribution to the development of the medical syste

Events